HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
PYY
peptide YY
Chromosome 17 · 17q21.31
NCBI Gene: 5697Ensembl: ENSG00000131096.12HGNC: HGNC:9748UniProt: P10082
138PubMed Papers
20Diseases
0Drugs
0Pathogenic Variants
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
receptor ligand activityG protein-coupled receptor bindingprotein bindingnegative regulation of eating behaviorHyperammonemia due to N-acetylglutamate synthetase deficiencyhyperammonemia due to N-acetylglutamate synthase deficiencyobesityobesity due to melanocortin 4 receptor deficiency
✦AI Summary

Peptide YY (PYY) is a gut hormone secreted by colonic L cells that functions as a key regulator of appetite, metabolism, and gastrointestinal physiology 1. PYY mediates its effects primarily through Y2 receptor activation in the hypothalamus to suppress food intake and promote satiety 2. The hormone is released from distal gut in response to nutrient ingestion and acts as a postprandial satiety signal 1. Beyond appetite suppression, PYY exhibits broader metabolic and protective functions. It improves pancreatic beta-cell survival and function through Y1 receptor activation, with therapeutic implications for diabetes management 2. PYY also attenuates colonic inflammation via neural pathways and demonstrates antitrophic properties in the pancreas by decreasing cytokine and amylase release 34. The hormone's secretion from human enteroendocrine L cells shows site-specific variation, with greater release in distal colon regions and declining production with age 5. Clinically, PYY elevation represents a therapeutic target for obesity management. Interventions increasing colonic propionate or inhibiting MGAT2 increase plasma PYY levels, reduce energy intake, and prevent weight gain in humans 67. These findings position PYY-based therapeutics as promising approaches for obesity, metabolic dysfunction, and gastrointestinal inflammation management.

Sources cited
1
PYY is released from distal gut in response to nutrient ingestion, with PYY3-36 reducing food intake and mediating postprandial satiety
PMID: 24732932
2
PYY suppresses appetite through Y2 receptor activation and improves pancreatic beta-cell survival/function via Y1 receptor activation
PMID: 29412828
3
PYY slows gastric emptying, suppresses appetite, and attenuates colonic inflammation via neural pathways
PMID: 40723884
4
PYY exhibits immune and antitrophic properties in pancreas by decreasing cytokine and amylase release
PMID: 17194501
5
PYY is co-secreted from colonic L cells with greater release in distal colon regions and declining production with aging
PMID: 37739120
6
Colonic propionate delivery increases plasma PYY and reduces energy intake and weight gain in overweight humans
PMID: 25500202
7
MGAT2 inhibition increases plasma PYY and decreases body weight in humans with obesity
PMID: 36323235
Disease Associationsⓘ20
hyperammonemia due to N-acetylglutamate synthase deficiencyOpen Targets
0.32Weak
Hyperammonemia due to N-acetylglutamate synthetase deficiencyOpen Targets
0.32Weak
obesityOpen Targets
0.13Weak
obesity due to melanocortin 4 receptor deficiencyOpen Targets
0.07Suggestive
irritable bowel syndromeOpen Targets
0.05Suggestive
osteomesopyknosisOpen Targets
0.05Suggestive
obesity due to pro-opiomelanocortin deficiencyOpen Targets
0.05Suggestive
obesity due to prohormone convertase I deficiencyOpen Targets
0.05Suggestive
type 2 diabetes mellitusOpen Targets
0.05Suggestive
acanthosis nigricansOpen Targets
0.05Suggestive
Prader-Willi syndromeOpen Targets
0.05Suggestive
colitisOpen Targets
0.05Suggestive
colorectal cancerOpen Targets
0.05Suggestive
osteosclerotic metaphyseal dysplasiaOpen Targets
0.04Suggestive
severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiencyOpen Targets
0.04Suggestive
obesity and hypopigmentationOpen Targets
0.04Suggestive
microcephaly, short stature, and impaired glucose metabolism 1Open Targets
0.04Suggestive
Alzheimer diseaseOpen Targets
0.04Suggestive
anorexia nervosaOpen Targets
0.04Suggestive
metabolic syndromeOpen Targets
0.04Suggestive
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Related Genes
NPY4RProtein interaction99%NPY4R2Protein interaction96%CCL28Protein interaction92%SSTProtein interaction91%FFAR4Protein interaction91%FFAR2Protein interaction90%
Tissue Expression6 tissues
Liver
100%
Brain
35%
Lung
26%
Ovary
19%
Bone Marrow
6%
Heart
0%
Gene Interaction Network
Click a node to explore
PYYNPY4RNPY4R2CCL28SSTFFAR4FFAR2
PROTEIN STRUCTURE
Preparing viewer…
PDB7RT9 · 1.90 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
1.77LoF Tolerant
pLIⓘ
0.00Tolerant
Observed/Expected LoF1.15 [0.73–1.77]
RankingsWhere PYY stands among ~20K protein-coding genes
  • #3,350of 20,598
    Most Researched138 · top quartile
  • #16,440of 17,882
    Most Constrained (LOEUF)1.77
Genes detectedPYY
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity.
PMID: 36323235
Cell Metab · 2022
1.00
2
Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults.
PMID: 25500202
Gut · 2015
0.90
3
Gut Hormones and Inflammatory Bowel Disease.
PMID: 40723884
Biomolecules · 2025
0.80
4
Alterations in GLP-1 and PYY release with aging and body mass in the human gut.
PMID: 37739120
Mol Cell Endocrinol · 2023
0.70
5
Crystal structures of human neuropeptide Y (NPY) and peptide YY (PYY).
PMID: 35180645
Neuropeptides · 2022
0.60